Entera Bio advances EB613 toward Phase 3 osteoporosis trial, targets late 2026 site activation
The company reported third-quarter 2026 results alongside plans for its first Phase 3 trial site and new executive and board hires ahead of pivotal testing of its oral osteoporosis tablet.
SEC filing